Page 56 - Read Online

Malone et al. J Cancer Metastasis Treat 2021;7:40 https://dx.doi.org/10.20517/2394-4722.2021.37 Page 3 of 18

Table 1. Sites of metastasis of primary breast cancer
Study Subtype Location of single metastasis % of sample Overall survival (months)
Niwinska et al. [7] Luminal/HER2- Brain 15 (0.2-56)*
HER2+ Brain 9 (0.6-3.4)*
TNBC Brain 3.7 (0.5-52)*
[8]
Chen et al. Bone 35.60% 31
Brain 1.70% 11 #
Liver 6.40% 19
Lung 9.30% 20
[9]
Wu et al. Luminal A Bone 58.52% 14.66 ± 12.83
Brain 4.30%
Liver 15.48%
Lung 21.70%
Luminal B Bone 47.28% 9.62 ± 10.96
Brain 5.89%
Liver 25.65%
Lung 21.17%
HER2+ Bone 34.49% 11.30 ± 11.71
Brain 8.31%
Liver 31.72%
Lung 25.48%
TNBC Bone 36.39% 12.48 ± 12.23
Brain 9.12%
Liver 22.40%
Lung 32.09%
[10]
Gong et al. Luminal A Bone 797% 36
Brain 1.2%
Liver 8.1%
Lung 11.0%
Luminal B Bone 61.0% 44
Brain 1.6%
Liver 20.3%
Lung 17.1%
HER2+ Bone 35.8% 34
Brain 3.4%
Liver 32.7%
Lung 28.1%
TNBC Bone 43.0% 13
Brain 5.1%
Liver 18.9%
Lung 33.1%
[11]
Gu et al. TNBC Bone 40% 13
Brain 6% 5
Liver 16% 13
Lung 37% 14
Studies reporting subtypes of primary breast cancer and their site of metastasis and the percent of patients exhibiting the metastasis in that
location, as well as the overall survival of the patients in the study with the designated metastasis. In some of the studies listed below the reports
did not specifically correlate overall survival with site of metastasis or molecular subtype. *Indicates survival from detection of brain metastases;
#
limited number of patients.